The customer observed falsely elevated ca 19-9 results generated with the architect ca 19-9xr reagents.The following data was provided (u/ml).Tested in (b)(6) 2016: 548.Previous results provided were 122 ((b)(6) 2016), 85, ((b)(6) 2016), 98 ((b)(6) 2016), and 77, (b)(6) 2016.The patient was diagnosed with diabetes , hyperlipidemia, and hypertension.Diagnostic tests including ct, echo, mri, and pet were completed after the elevated (b)(6) 2016 test and showed no tumor.Iv contrast (18f-fdg (the fluoro-deoxy-glucose) was administered for the positron emission tomography (pet) scan.The patient was not diagnosed with and was not being monitored for pancreatic cancer.No further impact to patient management was reported and no further details are known.The event caused unnecessary administration of iv contrast for a pet scan.
|
Investigation of the customer issue included a review of the complaint text, a search for similar complaints, a review of labeling and accuracy testing.No adverse trend was identified for the customer's issue.Labeling was reviewed and found to be adequate.The product was not available for return.An internal panel was tested with retained kits of the likely cause reagent lot and accuracy testing met all specifications.Based on all available information and abbott diagnostics' complaint investigation, the assay performed as intended and no product deficiency was identified.
|